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Antipolis, FranceFragile X-associated tremor ataxia syndrome (FXTAS) is a rare
disorder associated to the presence of the fragile X premuta-
tion, a 55–200 CGG repeat expansion in the 50 UTR of the
FMR1 gene. Two main neurological phenotypes have been
described in carriers of the CGG premutation: (1) neurodeve-
lopmental disorders characterized by anxiety, attention deﬁcit
hyperactivity disorder (ADHD), social deﬁcits, or autism spec-
trum disorder (ASD); and (2) after 50 years old, the FXTAS
phenotype. This neurodegenerative disorder is characterized
by ataxia and a form of parkinsonism. Themolecular pathology
of this disorder is characterized by the presence of elevated
levels of Fragile X Mental Retardation 1 (FMR1) mRNA, pres-
ence of a repeat-associated non-AUG (RAN) translated
peptide, and FMR1 mRNA-containing nuclear inclusions.
Whereas in the past FXTAS was mainly considered as a late-
onset disorder, some phenotypes of patients and altered
learning and memory behavior of a mouse model of FXTAS
suggested that this disorder involves neurodevelopment. To
better understand the physiopathological role of the increased
levels of Fmr1mRNA during neuronal differentiation, we used
a small interfering RNA (siRNA) approach to reduce the abun-
dance of this mRNA in cultured cortical neurons from the
FXTAS mouse model. Morphological alterations of neurons
were rescued by this approach. This cellular phenotype is asso-
ciated to differentially expressed proteins that we identiﬁed by
mass spectrometry analysis. Interestingly, phenotype rescue is
also associated to the rescue of the abundance of 29 proteins
that are involved in various pathways, which represent putative
targets for early therapeutic approaches.Received 18 July 2019; accepted 8 September 2019;
https://doi.org/10.1016/j.omtn.2019.09.018.
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The Fragile X Mental Retardation 1 (FMR1) gene encodes the fragile
X mental retardation protein (FMRP), an RNA binding protein
whose functional absence causes fragile X syndrome (FXS), the
most common form of intellectual disability (ID) and autism spec-
trum disorder (ASD). The mutation in the FMR1 gene causing FXS
is the presence of a repeated sequence encompassing >200 CGG re-
peats in its 50 UTR. Hypermethylation of this sequence determines546 Molecular Therapy: Nucleic Acids Vol. 18 December 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpgene promoter inactivation, causing the silencing of the FMR1
gene.1 Although 6–54 CGG repeats in the 50 UTR of FMR1 is a poly-
morphism in normal individuals, a repeat sequence of variable length
(55–200 CGG repeats) represents the premutation1 that can cause
fragile X tremor ataxia syndrome (FXTAS) in patients over 50 years
of age.2,3 This is an adult-onset progressive neurodegenerative disor-
der leading to a variable combination of ataxia, essential tremor, gait
imbalance, parkinsonism, peripheral neuropathy, anxiety, and cogni-
tive decline, occurring predominantly in older men carrying the
premutation. It is known that people carrying the premutation have
a reduced hippocampal volume that correlates with impaired perfor-
mance in standardized tests of memory.3 At the cellular level, this
disorder is characterized by the presence of eosinophilic, ubiquitin-
positive nuclear inclusions, which have been observed throughout
the brain, with a high percentage being located in the hippocampus
of patients, as well as in the animal model of the disease.3,4 Inclusions
are negative for tau isoforms, alpha-synuclein, or polyglutamine
peptides, reﬂecting a new class of inclusion disorder.3 At the molecu-
lar level, FXTAS is characterized by an elevated (2- to 8-fold) level of
FMR1 mRNA, whereas the level of FMRP is normal or slightly
reduced in patients, as well in the CGG-KI mouse model.2–4
The FMR1 mRNA is a component of nuclear inclusions3. The
product of repeat-associated non-ATG (RAN) translation of
the FMR1 mRNA was also reported to be involved in the generation
of inclusions when overexpressed.5,6 Although FXTAS is a late-onset
disorder, it is also characterized by a set of developmental hallmarks,
such as self-reported memory problems, autism-related traits, atten-
tion deﬁcit hyperactivity disorder (ADHD), executive functioning,
and psychopathology.7 Knockin (KI) mouse models have been gener-
ated displaying both neurodegenerative and neurodevelopmentalThe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Role of Fmr1 mRNA Levels in Dendritic
Arborization
(A) RNA was prepared from cultured WT and knockin-
CGG (KI-CGG) neurons transduced with the control (C)
shRNA or two different shRNAs directed against Fmr1
mRNA (1a and 1b). The level of Fmr1 mRNA was
measured by qRT-PCR using specific primers. Ten
different experiments have been carried out for each
transduced lentivirus, and a reduction of Fmr1 levels
was observed by using both shRNAs. Results are pre-
sented as mean ± SEM; one-way ANOVA with Tukey’s
multiple comparisons test, **p < 0.01. (B) Representative
western blot analysis of cell cultures of cortical neurons
transduced with C, 1a, or1b shRNAs. FMRP (70 kDa)
and b-tubulin (50 kDa) were revealed with specific anti-
bodies. (C) Image of WT and KI-CGG cortical neurons
transduced with lentiviruses expressing C, 1a, or 1b
shRNAs. Scale bars: 20 mm. (D) Sholl analysis of WT and
KI cultured mouse cortical neurons transduced with C or
1a or 1b shRNAs. Reduced arborization of KI-CGG
neurons is rescued by Fmr1 knockdown. Two-
way ANOVA was used to compare KI-C and 1a treat-
ments: genotype F(2; 1,527) = 227.9, p < 0.0001;
treatment (34; 1,527) = 34.12, p < 0.0001; interaction F(68; 1,527) = 3.067, p < 0.0001; two-way ANOVA was used to compare KI-C and 1b treatments: genotype F(2;
1,318) = 293.6, ****p < 0.0001; treatment F(34; 1,318) = 36.21, ****p < 0.0001; interaction F(68; 1,318) = 3,803, p < 0.0001.
www.moleculartherapy.orgphenotypes. It was reported that neuronal abnormalities and behav-
ioral alterations in the animal model are present before the appear-
ance of neuronal inclusions. Indeed, cultured hippocampal neurons
obtained from a CGG-KI display shorter dendritic length and
reduced dendritic complexity.4,8–10 In CGG-KI mice, cortical migra-
tion is also affected. Indeed, at embryonic day (E) 17, a 2-fold higher
percentage of migrating neurons was detected to be oriented toward
the ventricle in wild-type (WT) compared with CGG-KImice.11 All of
these abnormalities were observed in inclusion-free cells, because
CGG-KI mice display ubiquitin-positive intranuclear inclusions in
neurons and astrocytes of the hippocampus and cerebellar internal
cell layer starting at 12 weeks of age.4,8,9,11 Here we investigated the
impact of normalization of Fmr1 mRNA levels on the morphology
and proteomics of cortical cultured neurons obtained from a FXTAS
mouse model (CGG-KI)8,9 before the generation of nuclear inclu-
sions. By this analysis we have obtained a deeper insight into the phys-
iopathological role of Fmr1mRNA levels in FXTAS and identiﬁed pu-
tative targetable pathways for early treatments.
RESULTS
Hippocampal neurons were isolated from knockin-CGG (KI-CGG)
E15.5 mice harboring the CGG premutated allele. It has been shown
that these mice display abnormal cortical neuron migration patterns
in utero.10,11 Furthermore, abnormal dendritic architecture and
reduced cellular viability have been observed in hippocampal primary
neurons of KI-CGG mice, where increased expression of Fmr1 is
already present even if nuclear inclusions are not detected.10 Indeed,
nuclear inclusions appear ﬁrst in the hippocampus of these mice at
the age of 3 months, whereas the same hallmark appears later in
the parietal neocortex.8,9 We decided to explore whether cultured
cortical neurons obtained from these mice have an abnormalmorphology of dendrites and axons during development before the
appearance of nuclear inclusions. We studied the dendritic arboriza-
tion of wild-type (WT) and KI-CGG cortical neurons by Sholl
analysis, as previously described,12 and observed that KI-CGG neu-
rons have a reduced arborization compared with controls (Figures
S1A and S1B). To assess whether Fmr1 mRNA levels impact the
morphology of these cultured neurons, we produced lentiviruses ex-
pressing two different shRNAs selectively reducing the expression of
Fmr1mRNA (sh-1a and sh-1b) and one shRNA control (sh-C),13 and
we used them to transduce cortical cultured neurons obtained from
WT and from KI-CGG mice. The infection was performed at 5
DIV (days in vitro), and RNA and proteins were prepared from these
cultures at 20 DIV. As expected,4,13 Fmr1mRNA levels were elevated
2-fold in cultured KI cortical neurons compared with WT. sh-1a
reduced Fmr1 transcript levels by 30%, whereas sh-1b reduced
them by 50%, (Figure 1A). FMRP levels are not changed in KI
cultured neurons compared with WT,10,13 and as previously shown
in patients.2,3 Similarly, the expression level of FMRP was not affected
by Fmr1 knockdown in KI neurons (Figure 1B), as we already
observed by transfecting ﬁbroblasts obtained from FXTAS patients
with the same shRNAs.13 We then analyzed the arborization of WT
and KI cortical neurons transduced with Fmr1 shRNAs. We
conﬁrmed that KI neurons transduced with the lentivirus expressing
the control shRNA (KI-C) are less arborized than WT
neurons transduced with the same lentivirus (Figures 1C and 1D).
However, KI neurons transduced with lentivirus expressing either
sh-1a or sh-1b displayed a normal dendritic arborization (Figures
1C and 1D).
In 2 DIV neurons we measured the axon length, and we found that
they are signiﬁcantly shorter in Fmr1-KI neurons compared withMolecular Therapy: Nucleic Acids Vol. 18 December 2019 547
Figure 2. Fmr1 mRNA Levels Are Associated to Axon Growth
(A) Representative pictures of 2 days in vitro cultured WT-C, KI-C, KI-1a, and KI-1b primary cortical neurons. Scale bars: 10 mm. (B) Histogram of axon length of WT and KI
cultured neurons transfected with C, 1a, or 1b shRNAs. Results show mean axon length ± SEM of 150 randomly selected cells for each condition from three independent
cultures. One-way ANOVA with Tukey’s multiple comparisons test, *p < 0.05.
Molecular Therapy: Nucleic AcidsWT (Figure S2). We conﬁrmed that KI-C neurons have shorter axons
than WT-C, but the length of these axons was normalized in KI-1a
and KI-1b neurons (Figures 2A and 2B).
We then focused on dendritic spine abnormalities. The absence of
FMRP causes a peculiar morphology of dendritic spines that has
been described in FXS patients and in the mouse model, where
it is particularly evident in young animals.14,15 Conversely, the
study of dendritic spines in the brain of FXTAS patients was never
reported, and in Fmr1 KI mice it was studied only in hippocampi
and in the visual cortex from adult animals, displaying an
increased length of spines.4,16 Here we studied the morphology
of dendritic spines of 20 DIV cultured cortical neurons. KI-C
spines are longer, denser, and larger than controls. All of these
hallmarks are rescued in KI-1a and KI-1b neurons (Figures 3A–
3D), indicating that the elevated level of Fmr1 mRNA causes a
set of morphological alterations in KI-CGG neurons. However,
the percentage of the different types of spines (thin, stubby, and
mushroom) is not signiﬁcantly different in the two genotypes (Fig-
ures 3E–3G).
To get deeper insight into the molecular pathology of FXTAS
cultured neurons, we performed a proteomic analysis of neurons
that have been transduced with control shRNA or with the
shRNAs targeting the Fmr1 mRNA. Protein extracts of three rep-
licates for each condition were analyzed by nano-liquid chroma-
tography-tandem mass spectrometry (nano-LC-MS/MS) after
tryptic digestion.17 A total of 487 proteins were identiﬁed (Table
S1), among which 251 have a ratio >2 (upregulation) or <0.5
(downregulation) for at least one of the three comparisons
(WT-C versus KI-C, WT-C versus KI-1a, and WT-C versus
KI-1b) with a p value <0.10. Interestingly, the abundance of 29
differentially expressed proteins is rescued after reduction of
Fmr1 mRNA by using both speciﬁc shRNAs (Table 1). Gene
Ontology analysis of these proteins reveals a signiﬁcant enrichment
of proteins involved in different biochemical pathways, among
which are GTP binding and RNA binding proteins (Figure 4;
Table S2).548 Molecular Therapy: Nucleic Acids Vol. 18 December 2019DISCUSSION
Two main neurological phenotypes have been described in carriers of
the CGG premutation: those exhibiting neurodevelopmental disor-
ders characterized by anxiety, ADHD, social deﬁcits, or ASD, and
after 50 years old, FXTAS, a neurodegenerative disorder.3 For some
time, nuclear inclusions have been considered as the cause of
neurodegeneration, whereas more recent studies suggest that nuclear
inclusions may represent a mechanism used by neurons to protect
themselves from toxic events.4,18–20 So far, two other main
physiopathological elements are known to underpin the FXTAS
phenotype: the elevated abundance of FMR1 mRNA2 and the
presence of a RAN polypeptide.5,6 We considered that it is crucial
to unravel the role of each element in the molecular pathology of
FXTAS to understand the progression of the disorder and its role
in pathophysiology. Indeed, it is interesting to remind that neuronal
abnormal dendritic morphology (e.g., reduced length and number of
dendrites that display longer spines) has been observed in FXTAS
neurons at a time of development when nuclear inclusions are not
detectable.3,4,8–11 These ﬁndings suggest that some developmental
abnormalities may contribute to the late manifestation of neurode-
generative process and/or that the disease appears, with subtle
phenotypes, earlier than predicted up to date. So far, no speciﬁc
treatment is available for FXTAS patients. A therapy based on
allopregnanolone was shown to improve cognitive functioning in pa-
tients with FXTAS and to partially alleviate some aspects of neurode-
generation, but no data are known for neurodevelopmental hall-
marks,21 opening the possibility to search for new targetable
pathways in young patients. In this study, we used a murine model
of FXTAS to investigate the impact that the reduced level of Fmr1
mRNA, but not of its encoded protein, has on the morphological
and molecular phenotypes of FXTAS cultured neurons. Certainly,
by reducing Fmr1 mRNA levels, we are also supposed to reduce
RAN levels, which is possibly involved in the pathophysiology of
FXTAS.6 However, that peptide was never detected at endogenous
levels in neurons so far.3,22
First, we deﬁned phenotypes that were never considered before
in cultured cortical neurons obtained from the FXTAS mouse
Figure 3. Reduction of Fmr1 mRNA Levels Normalizes Dendritic Spine Morphology in KI Cortical Neurons
(A) Representative high-resolution confocal images showing dendritic spine morphology were assessed using NeuronStudio software and compared with the measurement
obtained from control transduced neurons. Scale bars: 2 mm. All histograms present mean ± SEM values. Statistical significance was assessed by one-way ANOVA with
Tukey’s multiple comparisons test. (B–G) Histograms showing the mean ± SEM values of (B) protrusion frequency in the various cultures, *p < 0.05; (C) spine length, ***p <
0.001; (D) spine head size, ***p < 0.001; (E) percentage of thin spines; (F) percentage of stubby spines; and (G) percentage of mushroom spines.
www.moleculartherapy.orgmodel: axon length and dendrite morphology. All of these new phe-
notypes are detected in cells not yet displaying nuclear inclusions,
which are known to ﬁrst appear in hippocampal neurons of 12-
week-old KI-CGG mice.9 Interestingly, these animals have mild
learning and memory deﬁcits,4,9 and this behavioral phenotype is
consistent with the phenotype that we observed in cultured cortical
neurons. Importantly, we conﬁrm that these phenotypes are associ-
ated with the levels of Fmr1 mRNA because they are rescued after
the expression of shRNAs speciﬁcally targeting this mRNA. We can
deduce that an elevated abundance of Fmr1 mRNA may interfere
with normal RNA metabolism. We can predict that the overexpres-
sion of Fmr1mRNAmay also likely interfere with the normal activity
of RNA binding proteins or microRNAs (miRNAs) in neuronal soma,
and at the synapse by competing for their binding at speciﬁc sites or at
miRNA response elements (MREs).13 All of these considerations sug-
gest that Fmr1mRNAmetabolism can be regulated by a large number
of RNA binding proteins and can be co-regulated with a plethora of
other RNAs. For this reason, as the second step of our study, we
performed a differential proteomic analysis of neurons expressing
control or Fmr1-speciﬁc shRNAs, and we observed that a set of
proteins, whose expression is deregulated in KI-CGG neurons, is
normalized after treatment. Consistently, several proteins rescued
by Fmr1-speciﬁc shRNAs are RNA binding proteins (e.g., Tia1,Hnrnpll, and ROAA). In addition, some proteins whose levels were
rescued by the reduction of Fmr1 mRNA abundance are involved
in the regulation of actin cytoskeleton dynamics, which is known to
modulate the morphology of neurons and, in particular, of dendritic
spines. Defective synaptic actin regulation seems to be involved in
different neurodevelopmental and psychiatric disorders.23 Interest-
ingly, we have shown here that in KI-CGG neurons, dendritic spines
are more numerous, and they appear overall longer and with a larger
head, but the percentage of the various types of spines is unchanged.
These results are consistent with a previous study displaying longer,
but not immature, spines in the CGG-KI visual cortex.16 In addition,
our ﬁndings suggest that, at least at 20 DIV, the elevated levels of
Fmr1 mRNA do not interfere with the spine maturation process
but cause subtle abnormalities of their features, which may have an
impact on synaptic transmission. Other rescued proteins belong to
the Rab-GTPase family, a sub-class of the RAS superfamily, which
spatially and temporally orchestrates speciﬁc vesicular trafﬁcking
that is critical for synaptic function in neurons in brain develop-
mental disorders,24 as well as in Parkinson’s disease.25 Along the
same direction, another interesting protein is CLIP2, a cytoplasmic
linker factor that is considered as a mediator between organelles
and the cytoskeleton.26 Consistent with their role in neurons, mutants
of this class of proteins are associated with impaired cognitiveMolecular Therapy: Nucleic Acids Vol. 18 December 2019 549
Table 1. Proteins Differentially Expressed in the Different Samples Studied
Name
UniProt Accession
Number WT-C KI-C
WT-C/
Ki-C
Log (Fold
Change) p Value KI-1a
WT-C/
Ki-1a
Log (Fold
Change) p Value KI-1b
WT-C/
KI-1b
Log (Fold
Change) p Value
spjO89023jTPP1_MOUSE O89023 0.00 0.93 0.00 NA 0.00001 0.00 NA NA 1.00000 0.00 NA NA 1.00000
spjP05132jKAPCA_MOUSE P05132 5.16 10.17 0.51 0.29 0.00132 5.83 0.89 0.05 0.81905 1.08 0.03 0.81905
spjP21126jUBL4A_MOUSE P21126 0.33 1.53 0.21 0.67 0.04762 0.66 0.49 0.31 0.51266 0.85 0.07 0.51266
spjP21278jGNA11_MOUSE P21278 7.43 4.06 1.83 0.26 0.03470 6.49 1.14 0.06 0.69780 0.93 0.03 0.69780
spjP24369jPPIB_MOUSE P24369 8.43 12.31 0.68 0.16 0.03540 6.73 1.25 0.10 0.68137 0.85 0.07 0.68137
spjP30677jGNA14_MOUSE P30677 2.57 0.93 2.77 0.44 0.04928 2.40 1.07 0.03 0.88974 0.79 0.10 0.88974
spjP35283jRAB12_MOUSE P35283 5.82 3.08 1.89 0.28 0.00979 5.87 0.99 0.00 0.95886 1.06 0.02 0.95886
spjP52912jTIA1_MOUSE P52912 0.00 0.93 0.00 NA 0.00001 0.00 NA NA 1.00000 0.00 NA 1.00000
spjP56371jRAB4A_MOUSE P56371 5.81 3.08 1.89 0.28 0.00560 5.87 0.99 0.00 0.94159 1.12 0.05 0.94159
spjQ80TS3jAGRL3_MOUSE Q80TS3 0.97 2.16 0.45 0.35 0.01678 0.37 2.64 0.42 0.17665 2.53 0.40 0.17665
spjQ8BGH2jSAM50_MOUSE Q8BGH2 2.28 0.29 7.74 0.89 0.01329 2.07 1.10 0.04 0.79778 1.07 0.03 0.79778
spjQ8BHC4jDCAKD_MOUSE Q8BHC4 0.00 0.93 0.00 NA 0.00001 0.31 0.00 NA 0.37390 NA NA 0.37390
spjQ8CHT0jAL4A1_MOUSE Q8CHT0 2.94 0.63 4.64 0.67 0.02926 2.43 1.21 0.08 0.54007 1.51 0.18 0.54007
spjQ91ZR1jRAB4B_MOUSE Q91ZR1 5.82 3.68 1.58 0.20 0.02923 5.51 1.05 0.02 0.71442 1.12 0.05 0.71442
spjQ921F4jHNRLL_MOUSE Q921F4 0.97 0.00 N NA 0.00000 0.98 0.99 0.00 0.98875 1.24 0.09 0.98875
spjQ922D8jC1TC_MOUSE Q922D8 1.28 2.78 0.46 0.34 0.00809 0.92 1.40 0.15 0.72353 1.00 0.00 0.72353
spjQ99020jROAA_MOUSE Q99020 1.63 0.31 5.34 0.73 0.04589 1.69 0.97 0.02 0.90543 0.74 0.13 0.90543
spjQ99PU5jACBG1_MOUSE Q99PU5 2.92 1.55 1.88 0.27 0.01399 2.73 1.07 0.03 0.62466 1.12 0.05 0.62466
spjQ9CPY7jAMPL_MOUSE Q9CPY7 1.61 3.38 0.48 0.32 0.00921 2.00 0.81 0.09 0.53465 1.13 0.05 0.53465
spjQ9CW03jSMC3_MOUSE Q9CW03 0.33 1.53 0.21 0.67 0.04762 0.71 0.46 0.34 0.64890 0.85 0.07 0.64890
spjQ9CYR6jAGM1_MOUSE Q9CYR6 0.33 1.86 0.18 0.75 0.01091 0.00 N N 0.37390 1.04 0.02 0.37390
spjQ9DCN2jNB5R3_MOUSE Q9DCN2 4.53 6.79 0.67 0.18 0.00385 4.79 0.95 0.02 0.62926 1.01 0.00 0.62926
spjQ9WTX2jPRKRA_MOUSE Q9WTX2 0.33 1.53 0.21 0.67 0.04762 0.00 N N 0.37390 N N 0.37390
spjQ9Z0H8jCLIP2_MOUSE Q9Z0H8 4.51 8.09 0.56 0.25 0.04003 4.68 0.96 0.02 0.88427 0.80 0.10 0.88427
trjA0A087WPM2j
A0A087WPM2_MOUSE
A0A087WPM2 1.94 2.78 0.70 0.16 0.00099 1.64 1.18 0.07 0.61624 1.73 0.24 0.61624
trjA0AUM9jA0AUM9_MOUSE A0AUM9 0.00 0.93 0.00 NA 0.00001 0.00 NA NA 1.00000 NA NA 1.00000
trjD3YZ68jD3YZ68_MOUSE D3YZ68 39.80 47.10 0.84 0.07 0.03447 38.80 1.03 0.01 0.89853 1.09 0.04 0.89853
trjE9Q7C9jE9Q7C9_MOUSE E9Q7C9 7.46 9.91 0.75 0.12 0.03009 5.75 1.30 0.11 0.10120 0.94 0.03 0.10120
trjS4R232jS4R232_MOUSE S4R232 5.50 3.04 1.81 0.26 0.03279 5.50 1.00 0.00 0.99389 1.06 0.03 0.99389
NA, not applicable.
M
o
le
c
u
la
r
T
h
e
ra
p
y:
N
u
c
le
ic
A
c
id
s
5
5
0
M
o
le
c
u
la
r
T
h
e
ra
p
y:
N
u
c
le
ic
A
c
id
s
V
o
l.
1
8
D
e
c
e
m
b
e
r
2
0
1
94.79
0.38
7.98
9.91
3.24
5.51
0.32
5.19
0.38
2.13
0.00
1.95
5.19
0.78
1.29
2.19
2.61
1.43
0.38
0.32
4.48
0.00
5.62
1.12
0.00
36.50
7.97
5.17
Figure 4. Gene Ontology Classification of Rescued Proteins in KI-CGG Neurons
(A and B) The DAVID Gene Ontology Functional Annotation Clustering tool40 was used to show functional classification of rescued proteins in Ki-CGG neurons involved in (A)
nucleotide-GTP binding and (B) RNA binding.
www.moleculartherapy.orgfunctions.21,24,27 Importantly, we also found mitochondrial proteins
(e.g., pyrroline-5-carboxylate dehydrogenase [Aldh4a1/P5CDH]
and Samm50) that are deregulated in CGG-KI neurons, conﬁrming
the importance of mitochondria in the pathophysiology of FXTAS,
as previously reported by independent studies.28,29 This result sug-
gests that an altered mitochondrial function is probably involved in
early phenotypes of this disorder. Remarkably, the levels of those pro-
teins were normalized by the reduction of Fmr1 mRNA abundance.
Thus, our data show molecular alterations that may contribute to
explain the neurodevelopmental phenotypes of the mouse model
and patients carrying the CGG premutation, thus providing an indi-
cation for future early therapies to treat CGG-premutation carriers.
For instance, Aldh4a1/P5CDH is a mitochondrial matrix NAD(+)-
dependent dehydrogenase that catalyzes the second step of the pro-
line degradation pathway, converting pyrroline-5-carboxylate to
glutamate. Altered function of this enzyme can result in a deregula-
tion of the glutamate signaling, which is at the basis of various forms
of brain disorders, as well as of Parkinson’s disease.30,31 Thus,
Aldh4a1/P5CDH could be a therapeutic target for FXTAS patients
during different periods of life and phases of the disorder associated
with the CGG premutation. Other targets may be small GTPases byusing, in this case, a strategy based on the modulation of their regu-
lators, as recently proposed.32,33 In conclusion, by our approach, we
deﬁned altered pathways in FXTAS neurons that are due to the
increased levels of Fmr1mRNA and impact on neuronal morphology.
They represent the molecular pathology underpinning the late
FXTAS phenotype. In particular, differentially expressed proteins be-
tween WT and CGG-KI neurons are promising pharmacological
targetable molecules for early therapeutic intervention for FXTAS.
On the other side, future gene therapies could also target the
CGG-repeat by excising it, as already shown in an induced pluripo-
tent stem cell (iPSC) line.34
MATERIALS AND METHODS
Animals
The experiments were performed following the Animals in Research:
Reporting In Vivo Experiments (ARRIVE) guidelines.35 Fmr1
knockin (KI) and wild-type (WT)mice on a C57BL/6J congenic back-
ground were produced as described previously.36 All animals were
generated and housed in groups of four in standard laboratory condi-
tions (22C, 55% ± 10% humidity, and 12-h light/12-h dark diurnal
cycles) with food and water provided ad libitum. Animal care wasMolecular Therapy: Nucleic Acids Vol. 18 December 2019 551
Molecular Therapy: Nucleic Acidsconducted in accordance with the European Community Directive
2010/63/EU. All experiments were approved by the local ethics
committee (Comité d’Ethique en Expérimentation Animale
CIEPAL-AZUR N. 00788.01).
Lentivirus Generation
Lentivirus particles were produced as previously described.37
Axon Length Measurements
Dissociated neurons were transfected with lentivirus plasmids by
using Nucleofector as previously described.13 Neurons were cultured
for 48 h and then ﬁxed. Axons were labeled with anti-Tuj1 antibody,
and the size of individual growing axons (distance from the soma to
the tip of the axon) was manually measured using the ImageJ
software.15
Neuronal Culture and Dendritic Spine Morphology Analysis
Primary neurons were prepared from E15.5 pregnant C57BL/6
Fmr1CGG/y and WT mice as previously described.12,15 Neurons
(5 days in vitro) were transduced with lentivirus as previously
described.12 Transduced neurons (20 days in vitro) were rinsed
twice in PBS at room temperature (RT) after 19 h of transduction
and then ﬁxed with 4% paraformaldehyde and Triton-permeabi-
lized. Sequential confocal images (512  220 pixels; zoom 3.0;
average 4; speed 7) of GFP-expressing neurons were acquired
with a 63 oil-immersion lens (NA 1.4) on an inverted Zeiss
LSM780 confocal microscope. z series of seven to eight images of
randomly selected secondary dendrites were analyzed using the
NeuronStudio software, which allows for the automated detection
and quantiﬁcation of dendrite parameters and morphological clas-
siﬁcation, as previously performed.15
Protein Extraction and Western Blot Analysis
Immunoblotting was performed as follows: cells or grinded tissues
were homogenized in lysis buffer, and debris was removed by
centrifugation (20,000  g, 10 min, 4C).38 Protein content in
the supernatant was measured using the Bradford assay (Bio-
Rad), and samples were separated on NuPAGE Bis-Tris 4%–12%
gels in MOPS buffer. Separated proteins were transferred to nitro-
cellulose membranes (Bio-Rad). Membranes were blocked with
PBS-Tween (0.05%) and milk (5%), and incubated with primary
antibodies overnight.
Antibodies
The monoclonal 1C3 anti-FMRP antibody39 was used at a 1:1,000
dilution, the anti-Tuj1 (BioLegend; TUJ1 1-15-56) antibody was
used following the manufacturer’s instructions, and the monoclonal
anti-b-tubulin antibody (Sigma) was used at a 1:10,000 dilution.
qRT-PCR
qPCR was performed on a LightCycler 480 (Roche) with MasterMix
SYBRGreen (Roche) as previously described.13 Primers used to
amplify Fmr1 mRNA were previously reported.37552 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Protein Identification and Analysis
Proteomic analysis was performed as previously described17 and
resulted in the identiﬁcation of around 2,000 proteins for each condi-
tion. These proteins were then compared to highlight the proteins
identiﬁed under only one condition or under several conditions
(“on/off” effect) and to highlight proteins predominantly identiﬁed
in one condition relative to another (up if ratio >2, down if ratio
<0.5). In order to compile a short list of differentially regulated
proteins, a Student’s t test was performed after normalization of the
spectral count quantiﬁcation data. This allowed us to obtain a p value
used to make this short list: from the global alignment table of the
2,888 different proteins, we focused on proteins with a p value
threshold less than 0.10.
Statistical Analysis
Results are expressed as mean ± SEM. All statistical analyses were
based on biological replicates. Appropriate statistical tests used for
each experiment are described in the corresponding ﬁgure legends.
All statistical analyses were carried out using GraphPad Prism version
6.0e.
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